(in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Current assets | ||||
Cash | $4694 | $15148 | $16214 | $13735 |
Short term investments | $16626 | $15145 | $15251 | $14932 |
Net receivables | $2035 | $1824 | $1429 | $3107 |
Inventory | ||||
Total current assets | $29986 | $38253 | $38759 | $37532 |
Long term investments | $1122 | $1132 | $1122 | $1110 |
Property, plant & equipment | $3030 | $3342 | $3309 | $3234 |
Goodwill & intangible assets | $9550 | $9540 | $9539 | $9320 |
Total noncurrent assets | $17079 | $17652 | $17696 | $17244 |
Total investments | $17748 | $16277 | $16373 | $16042 |
Total assets | $47065 | $55905 | $56455 | $54776 |
Current liabilities | ||||
Accounts payable | $6569 | $17796 | $18422 | $17449 |
Deferred revenue | $266 | $7536 | $7378 | $7220 |
Short long term debt | $1796 | $2491 | $2479 | $2273 |
Total current liabilities | $8278 | $27823 | $28279 | $26942 |
Long term debt | $10213 | $9483 | $9722 | $9743 |
Total noncurrent liabilities | $11875 | $11078 | $11285 | $11200 |
Total debt | $12009 | $11974 | $12201 | $12016 |
Total liabilities | $30803 | $38901 | $39564 | $38142 |
Shareholders' equity | ||||
Retained earnings | $27540 | $28191 | $27468 | $26619 |
Other shareholder equity | -$999 | -$1503 | -$1226 | -$1113 |
Total shareholder equity | $16262 | $16949 | $16834 | $16577 |
(in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Current assets | ||||
Cash | $4694 | $5061 | $3394 | $4673 |
Short term investments | $16626 | $13881 | $13192 | $12554 |
Net receivables | $2035 | $1674 | $1814 | $1138 |
Inventory | ||||
Total current assets | $29986 | $26183 | $24893 | $23641 |
Long term investments | $1122 | $1129 | $921 | $2382 |
Property, plant & equipment | $3030 | $3221 | $3073 | $2371 |
Goodwill & intangible assets | $9550 | $9142 | $11092 | $4447 |
Total noncurrent assets | $17079 | $16872 | $19465 | $11328 |
Total investments | $17748 | $15010 | $14113 | $14936 |
Total assets | $47065 | $43055 | $44358 | $34969 |
Current liabilities | ||||
Accounts payable | $6569 | $5238 | $12798 | $12156 |
Deferred revenue | $266 | $286 | $254 | $318 |
Short long term debt | $1796 | $2390 | $2279 | $920 |
Total current liabilities | $8278 | $7914 | $15331 | $13394 |
Long term debt | $10213 | $9034 | $10541 | $6060 |
Total noncurrent liabilities | $11875 | $10507 | $12924 | $7847 |
Total debt | $12009 | $11424 | $12820 | $6980 |
Total liabilities | $30803 | $27744 | $28255 | $21241 |
Shareholders' equity | ||||
Retained earnings | $27540 | $25492 | $23086 | $20517 |
Other shareholder equity | -$999 | -$1304 | $42 | $391 |
Total shareholder equity | $16262 | $15311 | $16080 | $13728 |
(in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $26423 | $26747 | $26742 | |
Cost of revenue | $21745 | $22009 | $21858 | |
Gross Profit | $4678 | $4738 | $4884 | |
Operating activities | ||||
Research & development | ||||
Selling, general & administrative | $3271 | $3111 | $2979 | |
Total operating expenses | $3472 | $3302 | $3165 | |
Operating income | $1206 | $1436 | $1719 | |
Income from continuing operations | ||||
EBIT | $1202 | $1375 | $1711 | |
Income tax expense | $256 | $296 | $359 | |
Interest expense | $114 | $120 | $113 | |
Net income | ||||
Net income | $832 | $959 | $1239 | |
Income (for common shares) | $832 | $959 | $1239 |
(in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $106374 | $92870 | $77155 | |
Cost of revenue | $75690 | $61628 | ||
Gross Profit | $17180 | $15527 | ||
Operating activities | ||||
Research & development | ||||
Selling, general & administrative | $12671 | $10052 | ||
Total operating expenses | $102361 | $13380 | $10541 | |
Operating income | $3800 | $4986 | ||
Income from continuing operations | ||||
EBIT | $3969 | $4957 | ||
Income tax expense | $836 | $762 | $1307 | |
Interest expense | -$493 | $401 | $283 | |
Net income | ||||
Net income | $2489 | $2806 | $3367 | |
Income (for common shares) | $2806 | $3367 |
(in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
---|---|---|---|---|
Net income | $832 | $959 | $1239 | |
Operating activities | ||||
Depreciation | $235 | $226 | $218 | |
Business acquisitions & disposals | -$34 | -$116 | -$73 | |
Stock-based compensation | $53 | $51 | $38 | |
Total cash flows from operations | $1252 | $3176 | $6687 | |
Investing activities | ||||
Capital expenditures | -$234 | -$264 | -$223 | |
Investments | -$317 | -$353 | -$996 | |
Total cash flows from investing | -$3492 | -$585 | -$733 | -$1292 |
Financing activities | ||||
Dividends paid | -$431 | -$109 | -$111 | -$100 |
Sale and purchase of stock | -$379 | -$529 | -$94 | |
Net borrowings | -$201 | $177 | $582 | |
Total cash flows from financing | -$856 | -$1733 | $36 | $3279 |
Effect of exchange rate | ||||
Change in cash and equivalents | -$367 | -$1066 | $2479 | $8674 |
(in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
---|---|---|---|---|
Net income | $2806 | $2933 | $3367 | |
Operating activities | ||||
Depreciation | $845 | $713 | $616 | |
Business acquisitions & disposals | $2364 | -$4187 | -$709 | |
Stock-based compensation | $216 | $180 | $181 | |
Total cash flows from operations | $4587 | $2262 | $5639 | |
Investing activities | ||||
Capital expenditures | -$1120 | -$1316 | -$964 | |
Investments | -$2250 | -$1053 | -$1392 | |
Total cash flows from investing | -$3492 | -$1006 | -$6556 | -$3065 |
Financing activities | ||||
Dividends paid | -$431 | -$392 | -$354 | -$323 |
Sale and purchase of stock | -$2096 | -$58 | -$1771 | |
Net borrowings | -$1428 | $3733 | $1078 | |
Total cash flows from financing | -$856 | -$1914 | $3015 | -$1955 |
Effect of exchange rate | ||||
Change in cash and equivalents | -$367 | $1667 | -$1279 | $619 |
3 High-Potential S&P 500 Healthcare Stocks Offering 30%+ Upside | Investing.com
Investing.com
10 hours ago
|
Humana Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance
26 Mar 2024
|
Here’s how Wall Street analysts’ favorite stock picks performed over the past five years
Market Watch
26 Mar 2024
|
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
Zacks via Yahoo Finance
21 Mar 2024
|
Should You Pick Humana Stock After A 25% Fall This Year?
Forbes
21 Mar 2024
|
Hedge Funds and Insiders Are Buying These 10 Stocks
Insider Monkey via Yahoo Finance
21 Mar 2024
|
Select Medical's (SEM) Concentra Submits Confidential IPO Filing
Zacks via Yahoo Finance
19 Mar 2024
|
15 Worst Performing Stocks in S&P 500
Insider Monkey via Yahoo Finance
8 Mar 2024
|
Can You Afford Health Care in Retirement? - NerdWallet
Nerdwallet
7 Mar 2024
|
15 Best Places to Retire If You Have No Savings
Insider Monkey via Yahoo Finance
7 Mar 2024
|
Market cap | $42.72B |
---|---|
Enterprise value | $50.03B |
Shares outstanding | 122.22M |
Revenue | N/A |
---|---|
EBITDA | N/A |
EBIT | N/A |
Net Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
P/E ratio | N/A |
---|---|
EV/Sales | N/A |
EV/EBITDA | N/A |
EV/EBIT | N/A |
P/S ratio | N/A |
P/B ratio | 2.47 |
Book/Share | 141.22 |
Cash/Share | 38.40 |
EPS | N/A |
---|---|
ROA | N/A |
ROE | N/A |
Debt/Equity | 1.89 |
---|---|
Net debt/EBITDA | N/A |
Current ratio | 3.62 |
Quick ratio | 3.62 |